Drugs / vedroprevir
vedroprevir
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 24 trials | ||||||
| Phase 2 | NCT02226549 | Jul 2014 → Feb 2015 | chronic hepatitis C virus infection | Gilead Sciences | Completed | No outcome recorded |
| Phase 2 | NCT01805882 | Jan 2013 → Aug 2015 | chronic hepatitis C virus infection | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT01384383 | Aug 2011 → Jun 2013 | chronic hepatitis C virus infection | Gilead Sciences | Terminated | No outcome recorded |
| Phase 2 | NCT01371578 | Jul 2011 → Mar 2013 | chronic hepatitis C virus infection | Gilead Sciences | Completed | No outcome recorded |
| Comparator or background therapy5 trials | ||||||
| Phase 2 | NCT01434498 Comparator | Sep 2011 → Jan 2013 | chronic hepatitis C virus infection | Gilead Sciences | Completed | No outcome recorded |
| Phase 2 | NCT01435226 Comparator | Sep 2011 → Jan 2013 | chronic hepatitis C virus infection | Gilead Sciences | Completed | No outcome recorded |
| Phase 2 | NCT01356160 Comparator | Jul 2011 → Jun 2013 | chronic hepatitis C virus infection | Gilead Sciences | Completed | No outcome recorded |
| Phase 2 | NCT01353248 Comparator | May 2011 → Oct 2012 | chronic hepatitis C virus infection | Gilead Sciences | Completed | No outcome recorded |
| Phase 2 | NCT01271790 Comparator | Oct 2010 → Jan 2013 | chronic hepatitis C virus infection | Gilead Sciences | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | vedroprevir | “This study is to evaluate the antiviral efficacy, safety, and tolerability of combination therapy with ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) +...” NCT02226549 ↗ |
| Known as | GS-9451 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01435226 ↗ |
| Known as | VDV | “This study is to evaluate the antiviral efficacy, safety, and tolerability of combination therapy with ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) +...” NCT02226549 ↗ |
| Action | Inhibit | “This is an open label study to assess the safety, tolerability, and efficacy of treatment with GS-7977 with GS-5885, alone or in combination with GS-9669 and/or GS-9451...” NCT01805882 ↗ |
| Modality | Small molecule | — CHEMBL2013174 ↗ |
| Route | Oral | “GS-9451 tablet, 200 mg once daily (QD)” NCT01271790 ↗ |